| Autor: |
Cheson, B. D., Morschhauser, F., Assouline, S. E., Michallet, A., Tani, M., Paris, G., Sun, W., Atwal, S. K., Hong, W., Sarkozy, C. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p829-830, 2p |
| Abstrakt: |
Aggressive B-cell lymphoma subtypes, including diffuse large B-cell lymphoma not otherwise specified, gray zone lymphoma, follicular lymphoma grade 3b, high-grade B-cell lymphoma, and primary mediastinal large B-cell lymphoma or large B-cell lymphoma transformed from indolent B-cell, are eligible to enroll. B Introduction: b PRT2527 is a potent, highly selective cyclin-dependent kinase 9 (CDK9) inhibitor. A PHASE 1 STUDY EVALUATING PRT2527, A POTENT AND HIGHLY SELECTIVE CDK9 INHIBITOR, IN PATIENTS WITH SELECT RELAPSED/REFRACTORY B-CELL MALIGNANCIES. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text